Moreover, the trial of Lundin et al. [20] revealed that SGLT2 inhibition benefits patients with heart failure or those at risk of heart failure, irrespective of LV ejection fraction and the presence of T2DM. This evidence concerns the gene SLC5A2 and heart failure.